IRIS Accounts Production v25.1.3.33 00489549 Board of Directors 1.1.24 31.12.24 31.12.24 Medium entities true true false true true false false true false These accounts have been prepared in accordance with the provisions applicable to companies subject to the medium-sized companies regime. Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh004895492023-12-31004895492024-12-31004895492024-01-012024-12-31004895492022-12-31004895492023-01-012023-12-31004895492023-12-3100489549ns15:EnglandWales2024-01-012024-12-3100489549ns14:PoundSterling2024-01-012024-12-3100489549ns10:Director12024-01-012024-12-3100489549ns10:PrivateLimitedCompanyLtd2024-01-012024-12-3100489549ns10:MediumEntities2024-01-012024-12-3100489549ns10:Audited2024-01-012024-12-3100489549ns10:Medium-sizedCompaniesRegimeForDirectorsReport2024-01-012024-12-3100489549ns10:Medium-sizedCompaniesRegimeForAccounts2024-01-012024-12-3100489549ns10:FullAccounts2024-01-012024-12-3100489549ns10:OrdinaryShareClass12024-01-012024-12-3100489549ns10:Director32024-01-012024-12-3100489549ns10:RegisteredOffice2024-01-012024-12-3100489549ns10:Director22024-01-012024-12-3100489549ns5:CurrentFinancialInstruments2024-12-3100489549ns5:CurrentFinancialInstruments2023-12-3100489549ns5:ShareCapital2024-12-3100489549ns5:ShareCapital2023-12-3100489549ns5:SharePremium2024-12-3100489549ns5:SharePremium2023-12-3100489549ns5:CapitalRedemptionReserve2024-12-3100489549ns5:CapitalRedemptionReserve2023-12-3100489549ns5:RetainedEarningsAccumulatedLosses2024-12-3100489549ns5:RetainedEarningsAccumulatedLosses2023-12-3100489549ns5:ShareCapital2022-12-3100489549ns5:RetainedEarningsAccumulatedLosses2022-12-3100489549ns5:SharePremium2022-12-3100489549ns5:CapitalRedemptionReserve2022-12-3100489549ns5:RetainedEarningsAccumulatedLosses2023-01-012023-12-3100489549ns5:CapitalRedemptionReserve2023-01-012023-12-3100489549ns5:RetainedEarningsAccumulatedLosses2024-01-012024-12-3100489549ns5:CapitalRedemptionReserve2024-01-012024-12-310048954912024-01-012024-12-310048954912023-01-012023-12-3100489549ns15:UnitedKingdom2024-01-012024-12-3100489549ns15:UnitedKingdom2023-01-012023-12-3100489549ns5:TotalGeographicSegmentsIncludingAnyUnallocatedAmount2024-01-012024-12-3100489549ns5:TotalGeographicSegmentsIncludingAnyUnallocatedAmount2023-01-012023-12-3100489549ns10:HighestPaidDirector2024-01-012024-12-3100489549ns10:HighestPaidDirector2023-01-012023-12-3100489549ns5:OwnedAssets2024-01-012024-12-3100489549ns5:OwnedAssets2023-01-012023-12-3100489549ns10:OrdinaryShareClass12023-01-012023-12-3100489549ns5:LandBuildings2023-12-3100489549ns5:PlantMachinery2023-12-3100489549ns5:FurnitureFittings2023-12-3100489549ns5:LandBuildings2024-01-012024-12-3100489549ns5:PlantMachinery2024-01-012024-12-3100489549ns5:FurnitureFittings2024-01-012024-12-3100489549ns5:LandBuildings2024-12-3100489549ns5:PlantMachinery2024-12-3100489549ns5:FurnitureFittings2024-12-3100489549ns5:LandBuildings2023-12-3100489549ns5:PlantMachinery2023-12-3100489549ns5:FurnitureFittings2023-12-3100489549ns5:MotorVehicles2023-12-3100489549ns5:ComputerEquipment2023-12-3100489549ns5:MotorVehicles2024-01-012024-12-3100489549ns5:ComputerEquipment2024-01-012024-12-3100489549ns5:MotorVehicles2024-12-3100489549ns5:ComputerEquipment2024-12-3100489549ns5:MotorVehicles2023-12-3100489549ns5:ComputerEquipment2023-12-3100489549ns5:CostValuation2023-12-3100489549ns5:Subsidiary12024-01-012024-12-31004895491ns5:Subsidiary12024-01-012024-12-3100489549ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-3100489549ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-3100489549ns5:WithinOneYear2024-12-3100489549ns5:WithinOneYear2023-12-3100489549ns5:BetweenOneFiveYears2024-12-3100489549ns5:BetweenOneFiveYears2023-12-3100489549ns5:AllPeriods2024-12-3100489549ns5:AllPeriods2023-12-3100489549ns5:AcceleratedTaxDepreciationDeferredTax2024-12-3100489549ns5:AcceleratedTaxDepreciationDeferredTax2023-12-3100489549ns5:DeferredTaxation2023-12-3100489549ns5:DeferredTaxation2024-12-3100489549ns10:OrdinaryShareClass12024-12-310048954912024-01-012024-12-31
REGISTERED NUMBER: 00489549 (England and Wales)











Johnsons Veterinary Products Limited

Strategic Report, Report of the Directors and

Financial Statements

for the Year Ended 31 December 2024






Johnsons Veterinary Products Limited (Registered number: 00489549)

Contents of the Financial Statements
for the Year Ended 31 December 2024










Page

Company Information 1

Strategic Report 2

Report of the Directors 3

Report of the Independent Auditors 5

Income Statement 8

Other Comprehensive Income 9

Balance Sheet 10

Statement of Changes in Equity 11

Cash Flow Statement 12

Notes to the Cash Flow Statement 13

Notes to the Financial Statements 14


Johnsons Veterinary Products Limited

Company Information
for the Year Ended 31 December 2024







DIRECTORS: P N Gwynn
N M Franks


REGISTERED OFFICE: 5 Reddicap Trading Estate
Sutton Coldfield
West Midlands
B75 7DF


REGISTERED NUMBER: 00489549 (England and Wales)


SENIOR STATUTORY AUDITOR: Darren Barlow FCCA


AUDITORS: TC Group
Statutory Auditor
Sterling House
97 Lichfield Street
Tamworth
Staffordshire
B79 7QF


BANKERS: Barclays Bank Plc
166 The Parade
The Mall Shopping Centre
Sutton Coldfield
West Midlands
B72 1PH

Johnsons Veterinary Products Limited (Registered number: 00489549)

Strategic Report
for the Year Ended 31 December 2024


The directors present their strategic report for the year ended 31 December 2024.

REVIEW OF BUSINESS
2024 was a robust year for sales, sustained across the year and led by essential OTC health categories in specialist pet retail, particularly insecticidal medicinals. Cost of living pressures kept shoppers value conscious, yet they continued to prioritise insect control and trusted advice in store - an environment that suits JVP's positioning as a value for money, high quality brand trusted for over 100 years. But the year presented unique challenges with changing demand, regulatory obstacles and supply side hurdles. Global political tensions added friction to supply chains-rerouted shipping, variable freight rates and raw material price fluctuations.

Seasonality was favourable with warm, humid spells created ideal flea conditions; ticks were most active from spring into early summer with a secondary lift in autumn; and heated homes kept baseline flea pressure present year round. Regulatory change also shaped the market: implementation of updated Veterinary Medicines Regulations clarified advertising, online seller registration and packaging/labelling expectations, and there were selected AVM GSL category movements. For specialist UK pet shops this strengthened the role of compliant, advice led selling-amplified through our National Pet Shop Day campaign in late July and sustained in store education.

Operationally, the early months reset our cost base and prioritised compliance. Non costed packaging returned to usual levels; carriage rose with volume; and professional work included Irish entity set up. Q1 brought significant testing for key products, an uplift in carriage/storage, and one off facilities repairs & renewals. Margins were further pressured by some promotion activity and by some higher unit costs after switches in production lines. March added further stability testing and higher software licensing.

Through spring we invested in security and customer capability. Software spending covered penetration testing and additional licences; direct cost lines-origination, retail partner support and customer support stepped up to match activity levels. We also processed advertising charges and licence registrations. From mid year, modest price increases began to filter through our range.

The second half combined stronger sales with tighter margin management. Ideal flea conditions in July, coupled with National Pet Shop Day, supported specialist retail. Q3 was competitive as we embedded more efficient order flows, focused on IP and regulatory readiness (trademark work, legal/consultancy support) and increased QP activity ahead of inspection. In October, remaining price changes were processed on key lines with major retail partners and margin started to benefit while we monitored upcoming supplier increases. In parallel, we accelerated branding and new product development throughout 2024-refreshing visual identity and packs, advancing formulations and claims with additional testing, and progressing trademark protection-so the pipeline entering 2025 is stronger and better differentiated.

Year end performance reflected disciplined execution. Elevated vendor discounts helped reduce overheads and overhead recovery per pack improved; Q4 ranked strongly despite aerosols softening. December closed with planned site improvements, higher distribution related direct costs in line with volume and service, increased staffing to support growth and compliance, and professional fees elevated by trademark and HSE/regulatory work. Overall, amid geopolitical supply chain uncertainty and household budget pressure, Johnson's sustained robust sales, preserved its value for money, high quality promise, and exited the year with improving margins and an accelerated innovation and branding campaign. We would like to thank all parties involved including our loyal customers as we look to 2025 and beyond.

ON BEHALF OF THE BOARD:





P N Gwynn - Director


23 September 2025

Johnsons Veterinary Products Limited (Registered number: 00489549)

Report of the Directors
for the Year Ended 31 December 2024


The directors present their report with the financial statements of the company for the year ended 31 December 2024.

PRINCIPAL ACTIVITY
The principal activity of the company in the year under review was that of the manufacture and distribution of pet care products.

DIVIDENDS
Results for the year are shown on page 8.

Dividends for the year are shown in note 7 to the accounts on page 17.

EVENTS SINCE THE END OF THE YEAR
Information relating to events since the end of the year is given in the notes to the financial statements.

DIRECTORS
The directors shown below have held office during the whole of the period from 1 January 2024 to the date of this report.

P N Gwynn
N M Franks

Other changes in directors holding office are as follows:

Mrs J R Johnson - resigned 4 September 2024

MARKET VALUE OF LAND AND BUILDINGS
In the opinion of the Directors, the market value of the Company's freehold property is in excess of the current net book value but as the property is held for the purpose of trade and not resale, the excess is not considered to be of significance to members.

STATEMENT OF DIRECTORS' RESPONSIBILITIES
The directors are responsible for preparing the Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

-select suitable accounting policies and then apply them consistently;
-make judgements and accounting estimates that are reasonable and prudent;
-prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS
So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

Johnsons Veterinary Products Limited (Registered number: 00489549)

Report of the Directors
for the Year Ended 31 December 2024


AUDITORS
The auditors, TC Group, will be proposed for re-appointment at the forthcoming Annual General Meeting.

ON BEHALF OF THE BOARD:





P N Gwynn - Director


23 September 2025

Report of the Independent Auditors to the Members of
Johnsons Veterinary Products Limited


Opinion

We have audited the financial statements of Johnsons Veterinary Products Limited ('the 'company') for the year ended 31 December 2024 which comprise the statement of comprehensive income, the balance sheet, the statement of changes in equity and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 31 December 2024 and of its profit for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of the report.

Other information
The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of our audit:

- the information given in the directors’ report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the directors’ report has been prepared in accordance with applicable legal requirements.

Report of the Independent Auditors to the Members of
Johnsons Veterinary Products Limited


Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors’ remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemption in preparing the directors’ report and take advantage of the small companies exemption from the requirement to prepare a strategic report.

Responsibilities of directors
As explained more fully in the Statement of Directors' Responsibilities set out on page three, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities, including fraud

The objectives of our audit, in respect to fraud, are: to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses; and to respond appropriately to fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both those charged with governance of the entity and its management.

Report of the Independent Auditors to the Members of
Johnsons Veterinary Products Limited


Our approach was as follows:

- we identified areas of laws and regulations that could reasonably be expected to have a material effect on the financial statements from our general commercial and sector experience, and through discussion with the directors and other management (as required by auditing standards), and discussed with the directors and other management the policies and procedures regarding compliance with laws and regulations;
- we considered the legal and regulatory frameworks directly applicable to the financial statements reporting framework (FRS 102 and the Companies Act 2006) and the relevant tax compliance regulations in the UK;
- we considered the nature of the industry, the control environment and business performance, including the key drivers for management¡¦s remuneration;
- we communicated identified laws and regulations throughout our team and remained alert to any indications of non-compliance throughout the audit;
- we considered the procedures and controls that the company has established to address risks identified, or that otherwise prevent, deter and detect fraud; and how senior management monitors those programmes and controls. -
- we considered how the directors and management respond to risks of fraud and whether they have knowledge of any actual, suspected or alleged fraud;
- we performed detailed analytical procedures to identify and unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;

Based on this understanding we designed our audit procedures to identify non-compliance with such laws and
regulations. Where the risk was considered to be higher, we performed audit procedures to address each identified fraud risk. These procedures included: testing manual journals; reviewing the financial statement disclosures and testing to supporting documentation; performing analytical procedures; and enquiring of management, and were designed to provide reasonable assurance that the financial statements were free from fraud or error.

Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have detected some material misstatements in the financial statements, even though we have properly planned and performed our audit in accordance with auditing standards. For example, the further removed non-compliance with laws and regulations (irregularities) is from the events and transactions reflected in the financial statements, the less likely the inherently limited procedures required by auditing standards would identify it. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation. We are not responsible for preventing non-compliance and cannot be expected to detect non-compliance with all laws and regulations.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.




Darren Barlow FCCA (Senior Statutory Auditor)
for and on behalf of TC Group
Statutory Auditor
Sterling House
97 Lichfield Street
Tamworth
Staffordshire
B79 7QF

23 September 2025

Johnsons Veterinary Products Limited (Registered number: 00489549)

Income Statement
for the Year Ended 31 December 2024

2024 2023
Notes £    £    £   

TURNOVER 3 12,074,811 11,272,953

Cost of sales 9,351,124 8,632,929
GROSS PROFIT 2,723,687 2,640,024

Distribution costs 288,377 257,818
Administrative expenses 1,016,337 1,039,098
1,304,714 1,296,916
1,418,973 1,343,108

Other operating income (1,589 ) 263
OPERATING PROFIT 5 1,417,384 1,343,371

Interest receivable and similar income 76,488 46,825
PROFIT BEFORE TAXATION 1,493,872 1,390,196

Tax on profit 6 373,011 339,170
PROFIT FOR THE FINANCIAL YEAR 1,120,861 1,051,026

Johnsons Veterinary Products Limited (Registered number: 00489549)

Other Comprehensive Income
for the Year Ended 31 December 2024

2024 2023
Notes £    £   

PROFIT FOR THE YEAR 1,120,861 1,051,026


OTHER COMPREHENSIVE INCOME - -
TOTAL COMPREHENSIVE INCOME FOR
THE YEAR

1,120,861

1,051,026

Johnsons Veterinary Products Limited (Registered number: 00489549)

Balance Sheet
31 December 2024

2024 2023
Notes £    £    £   
FIXED ASSETS
Tangible assets 8 1,510,312 1,526,854
Investments 9 2 2
1,510,314 1,526,856

CURRENT ASSETS
Stocks 10 2,211,213 1,703,333
Debtors 11 1,249,303 1,412,672
Cash at bank and in hand 2,899,094 2,815,955
6,359,610 5,931,960
CREDITORS
Amounts falling due within one year 12 1,124,279 1,325,032
NET CURRENT ASSETS 5,235,331 4,606,928
TOTAL ASSETS LESS CURRENT
LIABILITIES

6,745,645

6,133,784

PROVISIONS FOR LIABILITIES 14 11,736 12,536
NET ASSETS 6,733,909 6,121,248

CAPITAL AND RESERVES
Called up share capital 15 847 847
Share premium 461,076 461,076
Capital redemption reserve 1,317 1,317
Retained earnings 6,270,669 5,658,008
SHAREHOLDERS' FUNDS 6,733,909 6,121,248

The financial statements were approved by the Board of Directors and authorised for issue on 23 September 2025 and were signed on its behalf by:





P N Gwynn - Director


Johnsons Veterinary Products Limited (Registered number: 00489549)

Statement of Changes in Equity
for the Year Ended 31 December 2024

Called up Capital
share Retained Share redemption Total
capital earnings premium reserve equity
£    £    £    £    £   
Balance at 1 January 2023 847 5,115,182 461,076 1,317 5,578,422

Changes in equity
Dividends - (508,200 ) - - (508,200 )
Total comprehensive income - 1,051,026 - - 1,051,026
Balance at 31 December 2023 847 5,658,008 461,076 1,317 6,121,248

Changes in equity
Dividends - (508,200 ) - - (508,200 )
Total comprehensive income - 1,120,861 - - 1,120,861
Balance at 31 December 2024 847 6,270,669 461,076 1,317 6,733,909

Johnsons Veterinary Products Limited (Registered number: 00489549)

Cash Flow Statement
for the Year Ended 31 December 2024

2024 2023
Notes £    £   
Cash flows from operating activities
Cash generated from operations 1 866,819 1,749,731
Government grants (1,589 ) 262
Tax paid (335,654 ) (195,725 )
Net cash from operating activities 529,576 1,554,268

Cash flows from investing activities
Purchase of tangible fixed assets (23,550 ) (50,896 )
Sale of tangible fixed assets 8,825 -
Interest received 76,488 46,825
Net cash from investing activities 61,763 (4,071 )

Cash flows from financing activities
Amount withdrawn by directors - (83,200 )
Equity dividends paid (508,200 ) (508,200 )
Net cash from financing activities (508,200 ) (591,400 )

Increase in cash and cash equivalents 83,139 958,797
Cash and cash equivalents at beginning
of year

2

2,815,955

1,857,158

Cash and cash equivalents at end of year 2 2,899,094 2,815,955

Johnsons Veterinary Products Limited (Registered number: 00489549)

Notes to the Cash Flow Statement
for the Year Ended 31 December 2024


1. RECONCILIATION OF PROFIT BEFORE TAXATION TO CASH GENERATED FROM OPERATIONS

2024 2023
£    £   
Profit before taxation 1,493,872 1,390,196
Depreciation charges 29,759 33,868
Loss on disposal of fixed assets 1,508 -
Government grants 1,589 (263 )
Finance income (76,488 ) (46,825 )
1,450,240 1,376,976
(Increase)/decrease in stocks (507,880 ) 387,039
Decrease/(increase) in trade and other debtors 163,369 (47,596 )
(Decrease)/increase in trade and other creditors (238,910 ) 33,312
Cash generated from operations 866,819 1,749,731

2. CASH AND CASH EQUIVALENTS

The amounts disclosed on the Cash Flow Statement in respect of cash and cash equivalents are in respect of these Balance Sheet amounts:

Year ended 31 December 2024
31.12.24 1.1.24
£    £   
Cash and cash equivalents 2,899,094 2,815,955
Year ended 31 December 2023
31.12.23 1.1.23
£    £   
Cash and cash equivalents 2,815,955 1,857,158


3. ANALYSIS OF CHANGES IN NET FUNDS

At 1.1.24 Cash flow At 31.12.24
£    £    £   
Net cash
Cash at bank and in hand 2,815,955 83,139 2,899,094
2,815,955 83,139 2,899,094
Total 2,815,955 83,139 2,899,094

Johnsons Veterinary Products Limited (Registered number: 00489549)

Notes to the Financial Statements
for the Year Ended 31 December 2024


1. STATUTORY INFORMATION

Johnsons Veterinary Products Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Preparation of consolidated financial statements
During both the current and previous years the company's subsidiaries were dormant and immaterial and would be exempt from consolidation.

Key judgments in applying accounting policies and estimation uncertainty
The company makes estimates and assumptions concerning the future. Management are also required to exercise judgment in the process of applying the company’s accounting policies. Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are addressed below:

In preparing these financial statements, the directors have made the following judgments:

- Determine whether leases entered into by the company either as a lessor or a lessee are operating or lease or finance leases. These decisions depend on an assessment of whether the risks and rewards of ownership have been transferred from the lessor to the lessee on a lease by lease basis based on an evaluation of the terms and conditions of the arrangements, and accordingly whether the lease requires an asset and liability to be recognised in the statement of financial position.

- A provision is recognised when the company has a present legal or constructive obligation as a result of a past event for which it is probable that an outflow of resources will be required to settle the obligation and the amount can be reliably estimated. If the effect is material, provisions are determined by discounting the expected future cash flow at a rate that reflects the time value of money and the risks specific to the liability.

- Whether a present obligation is probable or not requires judgment. The nature and type of risks for these provisions differ and management’s judgment is applied regarding the nature and extent of obligations in deciding if an outflow of resources is probable or not.

- Depreciation and residual values. The Directors have reviewed the asset lives and associated residual values of all fixed asset classes, and have concluded that asset lives and residual values are appropriate.

The actual lives of the assets and residual values are assessed annually and may vary depending on a number of factors. In re-assessing asset lives, factors such as technological innovation, product life cycles and maintenance programmes are taken into account. Residual value assessments consider issues such as future market conditions, the remaining life of the asset and projects disposal values.

Turnover
Turnover represents amounts receivable for goods despatched net of VAT and trade discounts. Turnover is recognised on despatch of goods.

Johnsons Veterinary Products Limited (Registered number: 00489549)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024


2. ACCOUNTING POLICIES - continued

Tangible fixed assets
Depreciation is provided at the following rates in order to write off each asset over its estimated useful life.

Freehold property- not provided / 50 years
Plant and machinery- 10% on cost
Motor vehicles- 25% on cost
Computer hardware- 33% on cost
Computer software- 20% on cost
Office equipment- 25% on cost

No depreciation is provided in respect of one of the properties included within freehold land and buildings as, in the opinion of the directors, the market value is well in excess of the current net book value.

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost less any provision for impairment.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Cost is based on the cost of purchase on a first in, first out basis.

At each balance sheet date, stocks are assessed for any impairment or obsolescence. If either are apparent the carrying amount is reduced accordingly with the impairment loss recognised immediately in the Income Statement.

Financial instruments
The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities such as trade and other debtors and creditors, loans to or from related parties and investments in ordinary shares.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If such evidence is found, an impairment loss is recognised in the Income Statement.

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Johnsons Veterinary Products Limited (Registered number: 00489549)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024


2. ACCOUNTING POLICIES - continued

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Investments
Fixed asset investments are stated at cost less provision for diminution in value.

3. TURNOVER

The turnover and profit before taxation are attributable to the one principal activity of the company.

An analysis of turnover by geographical market is given below:

2024 2023
£    £   
United Kingdom 12,074,811 11,272,953
12,074,811 11,272,953

4. EMPLOYEES AND DIRECTORS
2024 2023
£    £   
Wages and salaries 1,414,346 1,265,580
Social security costs 137,674 125,497
Other pension costs 173,829 180,990
1,725,849 1,572,067

The average number of employees during the year was as follows:
2024 2023

Directors 3 3
Other 40 38
43 41

2024 2023
£    £   
Directors' remuneration 278,722 273,792
Directors' pension contributions to money purchase schemes 60,000 80,000

Information regarding the highest paid director is as follows:
2024 2023
£    £   
Emoluments etc 145,611 141,896
Pension contributions to money purchase schemes 30,000 40,000

Johnsons Veterinary Products Limited (Registered number: 00489549)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024


5. OPERATING PROFIT

The operating profit is stated after charging:

2024 2023
£    £   
Other operating leases 45,394 42,453
Depreciation - owned assets 29,759 33,867
Loss on disposal of fixed assets 1,508 -
Auditors' remuneration 11,450 10,500
Foreign exchange differences - 2,607

6. TAXATION

Analysis of the tax charge
The tax charge on the profit for the year was as follows:
2024 2023
£    £   
Current tax:
UK corporation tax 373,811 335,600

Deferred tax (800 ) 3,570
Tax on profit 373,011 339,170

Reconciliation of total tax charge included in profit and loss
The tax assessed for the year is lower than the standard rate of corporation tax in the UK. The difference is explained below:

2024 2023
£    £   
Profit before tax 1,493,872 1,390,196
Profit multiplied by the standard rate of corporation tax in the UK of 25%
(2023 - 23.521%)

373,468

326,988

Effects of:
Expenses not deductible for tax purposes 5,319 3,433
Income not taxable for tax purposes - (11,013 )
Capital allowances in excess of depreciation (5,776 ) -
Depreciation in excess of capital allowances - 19,762



Total tax charge 373,011 339,170

7. DIVIDENDS
2024 2023
£    £   
Final 169,400 169,400
Interim 338,800 338,800
508,200 508,200

Johnsons Veterinary Products Limited (Registered number: 00489549)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024


8. TANGIBLE FIXED ASSETS
Plant,
machinery Fixtures
Freehold and and
property computer fittings
£    £    £   
COST
At 1 January 2024 1,671,010 191,372 3,041
Additions - 23,400 -
Disposals - - -
At 31 December 2024 1,671,010 214,772 3,041
DEPRECIATION
At 1 January 2024 210,662 153,089 1,520
Charge for year 12,000 7,812 761
Eliminated on disposal - - -
At 31 December 2024 222,662 160,901 2,281
NET BOOK VALUE
At 31 December 2024 1,448,348 53,871 760
At 31 December 2023 1,460,348 38,283 1,521

Motor Computer
vehicles software Totals
£    £    £   
COST
At 1 January 2024 16,000 82,286 1,963,709
Additions - 150 23,550
Disposals (16,000 ) - (16,000 )
At 31 December 2024 - 82,436 1,971,259
DEPRECIATION
At 1 January 2024 3,667 67,917 436,855
Charge for year 2,000 7,186 29,759
Eliminated on disposal (5,667 ) - (5,667 )
At 31 December 2024 - 75,103 460,947
NET BOOK VALUE
At 31 December 2024 - 7,333 1,510,312
At 31 December 2023 12,333 14,369 1,526,854

Johnsons Veterinary Products Limited (Registered number: 00489549)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024


9. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£   
COST
At 1 January 2024
and 31 December 2024 115,577
PROVISIONS
At 1 January 2024
and 31 December 2024 115,575
NET BOOK VALUE
At 31 December 2024 2
At 31 December 2023 2

The company's investments at the Balance Sheet date in the share capital of companies include the following:

Prima Pet Care Limited
Registered office:
Nature of business: Dormant
%
Class of shares: holding
Ordinary 100.00

10. STOCKS
2024 2023
£    £   
Raw materials 723,814 643,270
Finished goods 1,487,399 1,060,063
2,211,213 1,703,333

11. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 1,199,725 1,290,384
Other debtors 12,354 10,854
Prepayments and accrued income 37,224 111,434
1,249,303 1,412,672

12. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade creditors 342,759 459,706
Tax 373,757 335,600
Social security and other taxes 56,559 39,662
VAT 213,861 354,640
Other creditors 11,520 1,411
Accruals and deferred income 125,823 134,013
1,124,279 1,325,032

Johnsons Veterinary Products Limited (Registered number: 00489549)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024


13. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:
2024 2023
£    £   
Within one year 1,622 10,573
Between one and five years - 733
1,622 11,306

14. PROVISIONS FOR LIABILITIES
2024 2023
£    £   
Deferred tax
Accelerated capital allowances 11,736 12,536

Deferred
tax
£   
Balance at 1 January 2024 12,536
Movement in the year (800 )
Balance at 31 December 2024 11,736

15. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
847 Ordinary £1 847 847

16. PENSION COMMITMENTS

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The pension cost charge represents contributions payable by the company to the fund and amounted to £173,829 (2023: £180,990). Contributions totalling £9,416 (2023: £nil) were payable to the fund at the reporting date and are included in creditors.

17. POST BALANCE SHEET EVENTS

Post year-end, but prior to the signing of the accounts, dividends of £169,400 (2023: £338,800) were paid to shareholders.